(Q44879420)

7 December 2017

0 references

Cost-efficacy comparison of inhaled fluticasone propionate and budesonide in the treatment of asthma (English)

1 reference

7 December 2017

1 reference

fluticasone propionate

1 reference

Stempel DA

1

1 reference

7 December 2017

Stanford RH

series ordinal

2

1 reference

7 December 2017

Thwaites R

series ordinal

3

1 reference

7 December 2017

Price MJ

series ordinal

4

1 reference

7 December 2017

publication date

1 December 2000

1 reference

7 December 2017

published in

Clinical Therapeutics

1 reference

7 December 2017

volume

22

1 reference

7 December 2017

issue

12

1 reference

7 December 2017

page(s)

1562-1574

1 reference

The cost of asthma: can it be reduced?

7 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983054-4

7 January 2021

Use of a pharmacy and medical claims database to document cost centers for 1993 annual asthma expenditures

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983054-4

7 January 2021

An economic evaluation of asthma in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983054-4

7 January 2021

A national estimate of the economic costs of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983054-4

7 January 2021

Mucosal inflammation in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983054-4

7 January 2021

Asthma and inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983054-4

7 January 2021

Mediators of immediate hypersensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983054-4

7 January 2021

Neuropeptides and asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983054-4

7 January 2021

Asthma and mast cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983054-4

7 January 2021

Leukotrienes and airway responses.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983054-4

7 January 2021

Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983054-4

7 January 2021

Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma. A quantitative light and electron microscopic study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983054-4

7 January 2021

Comparison of the efficacy and safety of inhaled fluticasone propionate 200 micrograms/day with inhaled beclomethasone dipropionate 400 micrograms/day in mild and moderate asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983054-4

7 January 2021

Clinical experience with fluticasone propionate in asthma: a meta-analysis of efficacy and systemic activity compared with budesonide and beclomethasone dipropionate at half the microgram dose or less

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983054-4

7 January 2021

The cost-effectiveness of inhaled fluticasone propionate and budesonide in the treatment of asthma in adults and children

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983054-4

7 January 2021

A blinded comparison of fluticasone propionate with budesonide via powder devices in adult patients with moderate-to-severe asthma: a clinical evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983054-4

7 January 2021

The episode-free day as a composite measure of effectiveness: an illustrative economic evaluation of formoterol versus salbutamol in asthma therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983054-4

7 January 2021

The cost of asthma in the emergency department and hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983054-4

7 January 2021

National Asthma Education and Prevention Program working group report on the cost effectiveness of asthma care

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983054-4

7 January 2021

Cost effectiveness of fluticasone and budesonide in patients with moderate asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983054-4

7 January 2021

10.1016/S0149-2918(00)83054-4

Identifiers

DOI

1 reference

7 December 2017

1 reference